

# **Day Break**


Wednesday, October 2, 2024











Abdullah Farhan
Abdullah.farhan@igi.com.pk

### Oil & Gas Marketing Companies

# Sep-24: Volumes Depict a Growth of +20%y/y; Up by +5%m/m

- Industry volumes for oil marketing companies for the month of Sep-24 increased by +20%y/y to 1.27mn ton bringing industry volumes for 3MFY24 to 3.68mn ton down by 3%Y/y. Motor Spirit (MS) / High Speed Diesel (HSD) sales were up by 22%/25%y/y during Sep-24 while Furnace Oil (FO) sales were down by 18%y/y. On a monthly basis, industry volumes are up by +5%m/m to 1.27mn ton during Sep-24 on the back of 8%/7%/2%m/m increase in HSD/FO/MS sales.
- During the 3MFY24, FO/HSD sales declined by 39%/1%y/y while MS sales remained flat. Company wise APL /PSO witnessed 19%/15%y/y decline in total sales while HASCOL reported +19%y/y growth during 3MFY24. Market share for PSO and APL dropped by 6.1% and 1.7% to 44% and 9% respectively during 3MFY24 against 50% and 11% in the same period last year, while SHEL and HASCOL reported 0.3% and 0.6% growth in market share during 3MFY24 respectively.
- Lower automobile sales and relatively higher prices are likely to keep demand growth restricted. Moreover, rise in HEV sales and potential launch of EV cars are also likely to restrict demand growth of petrol engines. However, cut in interest rate by SBP is likely to give slight push to passenger car sales. Potential hike in OMC margins are likely to support earnings amid depressed demand. Increase in power tariff and hike in gas prices would improve cash flow for PSO going forward and may unlock valuations.

### Sep-24: POL sales inclined by +20%y/y to 1.27mn ton

Industry volumes for oil marketing companies for the month of Sep-24 increased by +20%y/y to 1.27mn ton bringing industry volumes for 3MFY24 to 3.68mn ton down by 3%Y/y. Motor Spirit (MS) / High Speed Diesel (HSD) sales were up by 22%/25%y/y during Sep-24 while Furnace Oil (FO) sales were down by 18%y/y. On a monthly basis, industry volumes are up by +5%m/m to 1.27mn ton during Sep-24 on the back of 8%/7%/2%m/m increase in HSD/FO/MS sales.

During the 3MFY24, FO/HSD sales declined by 39%/1%y/y while MS sales remained flat. Company wise APL /PSO witnessed 19%/15%y/y decline in total sales while HASCOL reported +19%y/y growth during 3MFY24. Market share for PSO and APL dropped by 6.1% and 1.7% to 44% and 9% respectively during 3MFY24 against 50% and 11% in the same period last year, while SHEL and HASCOL reported 0.3% and 0.6% growth in market share during 3MFY24 respectively.



#### MS

MS sales augmented by +22%y/y to 0.63mn ton during Sep-24 while on sequential basis volumes are up by +2%m/m. HASCOL, SHEL, PSO and APL recorded +47%y/y, +17%y/y, +8%y/y and +7%y/y incline in volumes respectively during Sep-24. For 3MFY24, MS volumes are remained flat at 1.85mn ton. During 3MFY24, HASCOL and SHEL posted +10%y/y and +2%y/y growth respectively in volumes, whereas, PSO and APL recorded 15%y/y and 4%y/y drop in total MS sales. PSO and APL's market share dropped to 41% and 8.5% during 3MFY24 from 48% and 9% respectively in the same period last year. SHEL and HASCOL witnessed increase in market share to 9.5% and 4.2% respectively.

#### **HSD**

HSD sales jumped up by +25%y/y to 0.49mn ton in Sep-24 and on monthly basis volumes depicted a growth of +8%m/m. HASCOL, SHEL and PSO reported +166%y/y, +11%y/y and +6%y/y incline in sales during Sep-24 while APL recorded 3%y/y decline in volumes. This brings total 3MFY24 sales at 1.42mn ton down by 1%y/y. For 3MFY24, HASCOL posted +37%y/y incline in sales with market share for HASCOL increasing to 3.1%. Market share for PSO, APL and SHEL dropped by 10.0%, 1.0% and 0.4% respectively.

# FO

FO volumes plummetted by 18%y/y during Sep-24 to 0.07mn ton likely attributable to significant drop in demand from IPPs compared to last year. Volumes are up by +7%m/m during Sep-24. Total FO volumes are down by 39%y/y during 3MFY24 to 0.21mn ton. For 3MFY24, PSO and APL reported 22%y/y and 62%y/y decline in sales with PSO's market share increasing to 30.6% compared to 23.8% in 3MFY23, whereas, APL's market share dropped to 16.6% from 26.3% in the same period last year.

# Outlook

Lower automobile sales and relatively higher prices are likely to keep demand growth restricted. Moreover, rise in HEV sales and potential launch of EV cars are also likely to restrict demand growth of petrol engines. However, cut in interest rate by SBP is likely to give slight push to passenger car sales. Potential hike in OMC margins are likely to support earnings amid depressed demand. Increase in power tariff and hike in gas prices would improve cash flow for PSO going forward and may unlock valuations.



ASD         494.5         456.0         8%         394.2         25%         4,519.2         4,446.2         2%         1,415.4         1,437.0         -1%           O         69.0         64.5         7%         84.5         -18%         693.0         955.8         -27%         211.0         346.5         -39%           Others         73.4         70.3         4%         61.5         19%         645.3         560.1         15%         206.9         184.3         12%           Otal         1,271.7         1,215.7         5%         1,058.3         20%         11,276.9         11,391.9         -1%         3,683.9         3,814.1         -3%           AS         256.2         252.1         2%         238.1         8%         2,387.1         2,526.3         -6%         752.6         883.4         -15%           AS         256.2         252.1         2%         238.1         8%         2,387.1         2,526.3         -6%         752.6         883.4         -15%           AISD         219.0         201.0         9%         206.4         6%         2,209.2         2,393.6         -8%         633.8         787.1         -19%           Ot												
Notes	Exhibit: O	MC's Mo	nthly Sale	s Volun	ne (Sep-2	(4)						
Notes										0.45.405	0.4=140.4	
AS 634.8 624.9 2% 518.2 22% 5,419.4 5,429.8 0% 1,850.6 1,846.3 0% 1,850. 494.5 456.0 8% 394.2 25% 4,519.2 4,446.2 2% 1,415.4 1,437.0 -1% OD 69.0 64.5 7% 84.5 -18% 693.0 955.8 -27% 211.0 346.5 -39% ottal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% exemple		Sep-24	Aug-24	MoM	Sep-23	YoY	9MCY24	9MCY23	YoY	3MFY25	3MFY24	YoY
ASD         494.5         456.0         8%         394.2         25%         4,519.2         4,446.2         2%         1,415.4         1,437.0         -1%           O         69.0         64.5         7%         84.5         -18%         693.0         955.8         -27%         211.0         346.5         -39%           Others         73.4         70.3         4%         61.5         19%         645.3         560.1         15%         206.9         184.3         12%           otal         1,271.7         1,215.7         5%         1,058.3         20%         11,276.9         11,391.9         -1%         3,683.9         3,814.1         -3%           SSO         38         256.2         252.1         2%         238.1         8%         2,387.1         2,526.3         -6%         752.6         883.4         -15%           AISD         219.0         201.0         9%         206.4         6%         2,209.2         2,393.6         -8%         633.8         787.1         -19%           OD         13.7         16.9         -19%         11.7         17%         164.5         160.2         3%         64.5         82.4         -22%												
O 69.0 64.5 7% 84.5 -18% 693.0 955.8 -27% 211.0 346.5 -39% otal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% otal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% otal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% otal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% otal 1,271.7 1,215.7 5% 1,058.3 20% 11,276.9 11,391.9 -1% 3,683.9 3,814.1 -3% otal 219.0 201.0 9% 206.4 6% 2,209.2 2,393.6 -6% 752.6 883.4 -15% otal 219.0 201.0 9% 206.4 6% 2,209.2 2,393.6 -8% 633.8 787.1 -19% otal 548.5 528.4 4% 509.7 8% 534.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% otal 13.9 13.9 0% 49.7 7% 485.2 469.7 3% 156.7 163.3 -4% otal 13.9 13.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% otal 13.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% otal 13.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% otal 13.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42	MS						· · · · · · · · · · · · · · · · · · ·	· ·				
Others         73.4         70.3         4%         61.5         19%         645.3         560.1         15%         206.9         184.3         12% (otal           Octal         1,271.7         1,215.7         5%         1,058.3         20%         11,276.9         11,391.9         -1%         3,683.9         3,814.1         -3%           VSO           MSD         256.2         252.1         2%         238.1         8%         2,387.1         2,526.3         -6%         752.6         883.4         -15%           MSD         219.0         201.0         9%         206.4         6%         2,209.2         2,393.6         -8%         633.8         787.1         -19%           OD         13.7         16.9         -19%         11.7         17%         164.5         160.2         3%         64.5         82.4         -22%           Others         59.6         58.4         2%         53.4         12%         554.2         492.0         13%         171.8         160.4         7%           Others         59.6         58.4         2%         59.7         8%         5,314.8         5,572.1         -5%         1,622.8         1,913.3	HSD							•		•	-	
Otal         1,271.7         1,215.7         5%         1,058.3         20%         11,276.9         11,391.9         -1%         3,683.9         3,814.1         -3%           PSO           AIS         256.2         252.1         2%         238.1         8%         2,387.1         2,526.3         -6%         752.6         883.4         -15%           MSD         219.0         201.0         9%         206.4         6%         2,209.2         2,393.6         -8%         633.8         787.1         -19%           Others         59.6         58.4         2%         53.4         12%         554.2         492.0         13%         171.8         160.4         7%           Others         59.6         58.4         2%         53.4         12%         554.2         492.0         13%         171.8         160.4         7%           Others         59.6         58.4         2%         53.4         12%         554.2         492.0         13%         171.8         160.4         7%           Others         53.0         0%         49.7         7%         485.2         469.7         3%         156.7         163.3         -4%           <	FO											
AS 256.2 252.1 2% 238.1 8% 2,387.1 2,526.3 -6% 752.6 883.4 -15% ASD 219.0 201.0 9% 206.4 6% 2,209.2 2,393.6 -8% 633.8 787.1 -19% O 13.7 16.9 -19% 11.7 17% 164.5 160.2 3% 64.5 82.4 -22% Others 59.6 58.4 2% 53.4 12% 554.2 492.0 13% 171.8 160.4 7% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% APL  AS 53.0 53.0 0% 49.7 7% 485.2 469.7 3% 156.7 163.3 -4% ASD 44.1 43.8 1% 45.7 -3% 405.7 405.3 0% 125.5 142.2 -12% O 12.3 13.1 -7% 24.8 -51% 142.5 263.5 -46% 35.0 91.0 -62% Others 4.5 4.0 13% 3.2 42% 33.7 27.4 23% 12.5 8.7 43% Otal 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% ABSCOL  AS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% AISD 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% O 0% - 0% 0% 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% - 0% - 0% 0% 0% - 0% - 0% 0% - 0% 0% - 0% 0% - 0% 0% - 0% 0% - 0% 0% - 0% 0% - 0% 0% 0% - 0%	Others	73.4	70.3				645.3			206.9	184.3	
AS 256.2 252.1 2% 238.1 8% 2,387.1 2,526.3 -6% 752.6 883.4 -15% ASD 219.0 201.0 9% 206.4 6% 2,209.2 2,393.6 -8% 633.8 787.1 -19% O 13.7 16.9 -19% 11.7 17% 164.5 160.2 3% 64.5 82.4 -22% Others 59.6 58.4 2% 53.4 12% 554.2 492.0 13% 171.8 160.4 7% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% APL	Total	1,271.7	1,215.7	5%	1,058.3	20%	11,276.9	11,391.9	-1%	3,683.9	3,814.1	-3%
1SD 219.0 201.0 9% 206.4 6% 2,209.2 2,393.6 -8% 633.8 787.1 -19% O 13.7 16.9 -19% 11.7 17% 164.5 160.2 3% 64.5 82.4 -22% Others 59.6 58.4 2% 53.4 12% 554.2 492.0 13% 171.8 160.4 7% otal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% O 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	PSO											
TO 13.7 16.9 -19% 11.7 17% 164.5 160.2 3% 64.5 82.4 -22% orthers 59.6 58.4 2% 53.4 12% 554.2 492.0 13% 171.8 160.4 7% ortal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% ortal 548.5 528.4 4% 509.7 8% 5,314.8 5,572.1 -5% 1,622.8 1,913.3 -15% ortal 53.0 53.0 0% 49.7 7% 485.2 469.7 3% 156.7 163.3 -4% ortal 43.8 1% 45.7 -3% 405.7 405.3 0% 125.5 142.2 -12% ortal 13.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% ortal 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% ortal 13.9 13.9 0% 12.5 166% 111.2 130.3 -15% 44.1 32.2 37% ortal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% ortal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% ortal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% ortal 42.3 41.9 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% ortal 40.0 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45% ortal 40.0 3.4 16%	MS	256.2	252.1	2%	238.1	8%	2,387.1	2,526.3	-6%	752.6	883.4	-15%
Others         59.6         58.4         2%         53.4         12%         554.2         492.0         13%         171.8         160.4         7%           APL           APL         AS         53.0         53.0         0%         49.7         7%         485.2         469.7         3%         156.7         163.3         -4%           ASD         44.1         43.8         1%         45.7         -3%         405.7         405.3         0%         125.5         142.2         -12%           CO         12.3         13.1         -7%         24.8         -51%         142.5         263.5         -46%         35.0         91.0         -62%           Others         4.5         4.0         13%         3.2         42%         33.7         27.4         23%         12.5         8.7         43%           Otal         113.9         113.9         0%         123.3         -8%         1,067.1         1,165.9         -8%         329.8         405.2         -19%           HASCOL         44         4.9         -2%         5.5         166%         111.2         130.3         -15%         44.1         32.2         37%	HSD	219.0	201.0	9%	206.4	6%	2,209.2	2,393.6	-8%	633.8	787.1	-19%
fotal         548.5         528.4         4%         509.7         8%         5,314.8         5,572.1         -5%         1,622.8         1,913.3         -15%           APL           MS         53.0         53.0         0%         49.7         7%         485.2         469.7         3%         156.7         163.3         -4%           MSD         44.1         43.8         1%         45.7         -3%         405.7         405.3         0%         125.5         142.2         -12%           O         12.3         13.1         -7%         24.8         -51%         142.5         263.5         -46%         35.0         91.0         -62%           Others         4.5         4.0         13%         3.2         42%         33.7         27.4         23%         12.5         8.7         43%           Ottal         113.9         113.9         0%         123.3         -8%         1,067.1         1,165.9         -8%         329.8         405.2         -19%           ASS         27.2         26.6         2%         18.5         47%         191.3         230.6         -17%         77.8         70.8         10%           O	FO	13.7	16.9	-19%	11.7	17%	164.5	160.2	3%	64.5	82.4	-22%
APL  MS 53.0 53.0 0% 49.7 7% 485.2 469.7 3% 156.7 163.3 -4% 15D 44.1 43.8 1% 45.7 -3% 405.7 405.3 0% 125.5 142.2 -12% 100 12.3 13.1 -7% 24.8 -51% 142.5 263.5 -46% 35.0 91.0 -62% 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% 14ASCOL  MS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% 15D 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 100 - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Others	59.6	58.4	2%	53.4	12%	554.2	492.0	13%	171.8	160.4	7%
MS 53.0 53.0 0% 49.7 7% 485.2 469.7 3% 156.7 163.3 -4% 45D 44.1 43.8 1% 45.7 -3% 405.7 405.3 0% 125.5 142.2 -12% O 12.3 13.1 -7% 24.8 -51% 142.5 263.5 -46% 35.0 91.0 -62% Others 4.5 4.0 13% 3.2 42% 33.7 27.4 23% 12.5 8.7 43% otal 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% HASCOL  MS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% 45D 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% O - 0 - 0% - 0% - 0% 1.3 0.2 442% 0.9 0.1 1524% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% HEL  MS 59.9 59.7 0% 51.3 17% 530.9 539.5 -2% 176.1 172.4 2% 45D 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% 60 - 0 - 0% - 0/m - 3.7 -100% 0% 0 - 0% 0 - 0/m - 0/m - 3.7 -100% 0/m 0 - 0/m 0	Total	548.5	528.4	4%	509.7	8%	5,314.8	5,572.1	-5%	1,622.8	1,913.3	-15%
HSD 44.1 43.8 1% 45.7 -3% 405.7 405.3 0% 125.5 142.2 -12% 12.6 12.3 13.1 -7% 24.8 -51% 142.5 263.5 -46% 35.0 91.0 -62% 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% 143.5 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% 143.5 143.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 12.5 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 12.5 14.7 14.9 12.7 12.8 12.8 12.8 12.8 12.8 12.8 12.8 12.8	APL											
O 12.3 13.1 -7% 24.8 -51% 142.5 263.5 -46% 35.0 91.0 -62% Others 4.5 4.0 13% 3.2 42% 33.7 27.4 23% 12.5 8.7 43% otal 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% colored by the colored	MS	53.0	53.0	0%	49.7	7%	485.2	469.7	3%	156.7	163.3	-4%
Others 4.5 4.0 13% 3.2 42% 33.7 27.4 23% 12.5 8.7 43% fotal 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% test    #ASCOL  ### ASCOL  ### A	HSD	44.1	43.8	1%	45.7	-3%	405.7	405.3	0%	125.5	142.2	-12%
Total 113.9 113.9 0% 123.3 -8% 1,067.1 1,165.9 -8% 329.8 405.2 -19% HASCOL  MS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% HSD 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% HSD 0 - 0 0% - 0% - 0% - 0% - 0% - 0% - 0%	FO	12.3	13.1	-7%	24.8	-51%	142.5	263.5	-46%	35.0	91.0	-62%
HASCOL  MS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% 14.5 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 150 - 0% - 0% - 0% - 0% - 0% - 0% 1.3 0.2 442% 0.9 0.1 1524% 150.1 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% 150.1 1	Others	4.5	4.0	13%	3.2	42%	33.7	27.4	23%	12.5	8.7	43%
MS 27.2 26.6 2% 18.5 47% 191.3 230.6 -17% 77.8 70.8 10% ASD 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% CO 0% - 0% - 0% - 0% 0% - 0% Chlers 0.4 0.3 21% - 0% 1.3 0.2 442% 0.9 0.1 1524% Cotal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% CHEL  MS 59.9 59.7 0% 51.3 17% 530.9 539.5 -2% 176.1 172.4 2% ASD 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% CO - 0% - 0/6 1.3 17% 530.9 17.6 35% 9.7 6.7 45% CO - 0% 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45%	Total	113.9	113.9	0%	123.3	-8%	1,067.1	1,165.9	-8%	329.8	405.2	-19%
HSD 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 160 0% - 0% - 0% - 0% - 0% - 0% 1.3 0.2 442% 0.9 0.1 1524% 1504 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% 15HEL  MS 59.9 59.7 0% 51.3 17% 530.9 539.5 -2% 176.1 172.4 2% 14SD 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% 170 170 170 170 170 170 170 170 170 170	HASCOL											
HSD 14.7 14.9 -2% 5.5 166% 111.2 130.3 -15% 44.1 32.2 37% 160 0% - 0% - 0% - 0% - 0% - 0% 1.3 0.2 442% 0.9 0.1 1524% 1504 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% 15HEL  MS 59.9 59.7 0% 51.3 17% 530.9 539.5 -2% 176.1 172.4 2% 14SD 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% 170 170 170 170 170 170 170 170 170 170	MS	27.2	26.6	2%	18.5	47%	191.3	230.6	-17%	77.8	70.8	10%
O 0% - 0% - 0% - 0% 0% 0% 0% Others 0.4 0.3 21% - 0% 1.3 0.2 442% 0.9 0.1 1524% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 10% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 10% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 10% otal 42.3 41.9 1% otal 42.0 10% otal 42.3 41.9 1% otal 42.0 10% otal 42.3 41.9 10% otal 42.3 41.9 10% otal 42.3 41.9 10% otal 42.3 10% otal 42.3 41.9 10% otal 42.3 10% otal 42.3 41.9 10% otal 42.3 41	HSD	14.7	14.9			166%						37%
Others 0.4 0.3 21% - 0% 1.3 0.2 442% 0.9 0.1 1524% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 76% 303.8 361.1 -16% 122.7 103.0 19% otal 42.3 41.9 1% 24.0 19% otal 42.3 41.9 1% 24.0 19% otal 42.3 41.9 1% 24.0 19% otal 42.3 41.9 1% otal 42.3 41	FO											
Fotal         42.3         41.9         1%         24.0         76%         303.8         361.1         -16%         122.7         103.0         19%           SHEL           MS         59.9         59.7         0%         51.3         17%         530.9         539.5         -2%         176.1         172.4         2%           HSD         29.4         29.1         1%         26.4         11%         287.4         292.3         -2%         86.3         92.7         -7%           FO         -         -         0%         -         n/m         -         3.7         -100%         -         -         0%           Others         4.0         3.4         16%         2.2         79%         23.7         17.6         35%         9.7         6.7         45%	Others	0.4	0.3		_		1.3	0.2	442%	0.9	0.1	1524%
SHEL       MS     59.9     59.7     0%     51.3     17%     530.9     539.5     -2%     176.1     172.4     2%       HSD     29.4     29.1     1%     26.4     11%     287.4     292.3     -2%     86.3     92.7     -7%       FO     -     -     0%     -     n/m     -     3.7     -100%     -     -     0%       Others     4.0     3.4     16%     2.2     79%     23.7     17.6     35%     9.7     6.7     45%	Total				24.0							
MS 59.9 59.7 0% 51.3 17% 530.9 539.5 -2% 176.1 172.4 2% HSD 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% O - 0% - n/m - 3.7 -100% 0% Others 4.0 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45%	SHEL											
HSD 29.4 29.1 1% 26.4 11% 287.4 292.3 -2% 86.3 92.7 -7% CO 0% - n/m - 3.7 -100% 0% Others 4.0 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45%	MS	59.9	59.7	0%	51.3	17%	530.9	539.5	-2%	176.1	172.4	2%
O 0% - n/m - 3.7 -100% 0% Others 4.0 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45%	HSD											
Others 4.0 3.4 16% 2.2 79% 23.7 17.6 35% 9.7 6.7 45%	FO											
	Others	4.0					23.7			9.7		
55 5-15 176 50.0 1776 51E.0 555.1 176 ETE.1 ET1.0 676	Total											
ource: IGI Research, OCAC				170	00.0	11.75	0.2.0	033.1	170	_,_,	_,	0,0



# **Important Disclaimer and Disclosures**

Research Analyst(s) Certification: The Research Analyst(s) hereby certify that the views about the company/companies and the security/ securities discussed in this report accurately reflect his or her or their personal views and that he/she has not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report. The analyst(s) is principally responsible for the preparation of this research report and that he/she or his/her close family/relative does not own 1% or more of a class of common equity securities of the following company/companies covered in this report.

**Disclaimer:** The information and opinions contained herein are prepared by IGI Finex Securities Limited and is for information purposes only. Whilst every effort has been made to ensure that all the information (including any recommendations or opinions expressed) contained in this document (the information) is not misleading or unreliable, IGI Finex Securities Limited makes no representation as to the accuracy or completeness of the information. Neither, IGI Finex Securities Limited nor any director, officer or employee of IGI Finex Securities Limited shall in any manner be liable or responsible for any loss that may be occasioned as consequence of a party relying on the information. This document takes no account of the investment objectives, financial situation and particular needs of investors, who shall seek further professional advice before making any investment decision. The subject Company (ies) is a client of the IGI Finex Securities Limited and IGI Finex Securities offers brokerage services to Subject Company (ies) on a regular basis, in line with industry practice. This document and the information may not be reproduced, distributed or published by any recipient for any purpose. This report is not directed or intended for distribution to, or use by any person or entity not a client of IGI Finex Securities Limited, else directed for distribution.

Rating system: IGI Finex Securities employs three tier ratings system, depending upon expected total return (return is defined as capital gain exclusive of tax) of the security in stated time period, as follows:

### **Recommendation Rating System**

Buy if target price on aforementioned security (ies) is more than 10%, from its last closing price(s) Hold if target price on aforementioned security (ies) is in between -10% and 10%, from its last closing price(s) Sell if target price on aforementioned security (ies) is less than -10%, from its last closing price(s)

Valuation Methodology: To arrive at Target Prices, IGI Finex Securities uses different valuation methodologies including

- Discounted Cash Flow (DCF)
- Reserve Based DCF
- Dividend Discount Model (DDM)
- Justified Price to Book
- Residual Income (RI)
- Relative Valuation (Price to Earning, Price to Sales, Price to Book)

**Risk:** Investment in securities are subject to economic risk, market risk, interest rate risks, currency risks, and credit risks, political and geopolitical risks. The performance of company (ies) covered herein might unfavorably be affected by multiple factors including, business, economic, and political conditions. Hence, there is no assurance or guarantee that estimates, recommendation, opinion, etc. given about the security (ies)/company (ies) in the report will be achieved.

Basic Definitions and Terminologies used: Target Price: A price target is the projected price level of a financial security stated by an investment analyst or advisor. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment, Last Closing: Latest closing price, Market Cap.: Market capitalization is calculated by multiplying a company's shares outstanding by current trading price. EPS: Earnings per Share. DPS: Dividend per Share. ROE: Return on equity is the amount of net income returned as a percentage of shareholders' equity. P/E: Price to Earnings ratio of a company's share price to its per-share earnings. P/B: Price to Book ratio used to compare a stock's market value to its book value. DY: The dividend yield is dividend per share, divided by the price per share.

IGI Finex Securities Limited
Research Analyst(s)
Research Identity Number: I

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited



# **Contact Details**

### **Equity Sales**

Zaeem Haider Khan	Head of Equities	Tel: (+92-42) 35301405	zaeem.haider@igi.com.pk
Muhammad Naveed	Regional Manager (Islamabad & Upper North)	Tel: (+92-51) 2604861-62	muhammad.naveed@igi.com.pk
Syeda Mahrukh Hameed	Branch Manager (Lahore)	Tel: (+92-42) 38303564	mahrukh.hameed@igi.com.pk
Shakeel Ahmad	Branch Manager (Faisalabad)	Tel: (+92-41) 2540843-45	shakeel.ahmad1@igi.com.pk
Asif Saleem	Equity Sales (RY Khan)	Tel: (+92-68) 5871652-56	asif.saleem@igi.com.pk
Mehtab Ali	Equity Sales (Multan)	Tel: (+92-61) 4512003	mahtab.ali@igi.com.pk

### **Research Team**

Abdullah Farhan	Head of Research	Tel: (+92-21) 111-234-234 Ext: 912	abdullah.farhan@igi.com.pk
Sakina Makati	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 810	sakina.makati@igi.com.pk
Laraib Nisar	Research Analyst	Tel: (+92-21) 111-234-234 Ext: 974	laraib.nisar@igi.com.pk

### **IGI Finex Securities Limited**

Trading Rights Entitlement Certificate (TREC) Holder of Pakistan Stock Exchange Limited | Corporate member of Pakistan Mercantile Exchange Limited Website: www.igisecurities.com.pk

### **Head Office**

Suite No 701-713, 7th Floor, The Forum, G-20, Khayaban-e-Jami Block-09, Clifton, Karachi-75600 UAN: (+92-21) 111-444-001 | (+92-21) 111-234-234 Fax: (+92-21) 35309169, 35301780

Islamabad Office		
Mezzanine Floor, Office 5, 6 & 7, Kashmir Plaza,		
Block- B, Jinnah Avenue, Blue Area		
Tel: (+92-51) 2604861-2, 2604864, 2273439		
Fax: (+92-51) 2273861		
Rahim Yar Khan Office		
Plot # 12, Basement of Khalid Market,		
Model Town, Town Hall Road		
Tel: (+92-68) 5871652-3		
Fax: (+92-68) 5871651		

IGI Finex Securities Limited Research Analyst(s)

Research Identity Number: BRP009

© Copyright 2024 IGI Finex Securities Limited